A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent

Ravi Nagarajan, Gamal Abou-Mohamed, Tammy Myers, Robert William Caldwell

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Arbutamine, developed for use as a cardiac stress agent, was compared with isoproterenol and dobutamine in anesthetized dogs for cardiovascular actions prior to and after beta-adrenergic blockade with propranolol. The efficacy and safety of arbutamine were also evaluated in a canine model of myocardial ischemia obtained by partially occluding the left anterior descending coronary artery. Comparison of hemodynamic variables in normal dogs showed that arbutamine was approximately equipotent to isoproterenol in increasing heart rate and cardiac contractility, and in decreasing total peripheral vascular resistance and mean arterial blood pressure. Arbutamine was 210 times more potent than dobutamine in increasing cardiac contractility by 70%; however, at this dose dobutamine exhibited a negative chronotropic response. Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance. In dogs subjected to partial left anterior descending coronary artery occlusion, arbutamine produced significant ST-segment deflections, beginning at a dose of 0.1 nmol/kg/min. Impairment of segment shortening, reflecting cardiac wall motion abnormality, was evident at a dose of 0.3 nmol/kg/min. Isoproterenol did not cause significant changes in these parameters. These results show that arbutamine is capable of producing graded increments in cardiac contractility and rate before and after beta-adrenergic blockade in normal dogs. In dogs subjected to coronary artery occlusion, it is capable of provoking myocardial ischemia at dose levels devoid of toxicity.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalCardiovascular Drugs and Therapy
Volume10
Issue number1
DOIs
StatePublished - Jan 1 1996

Fingerprint

Catecholamines
Dobutamine
Pharmacology
Vascular Resistance
Dogs
Isoproterenol
Adrenergic Agents
Coronary Vessels
Coronary Occlusion
Propranolol
Myocardial Ischemia
Arterial Pressure
Heart Rate
Myocardial Contraction
arbutamine
Canidae
Hemodynamics
Safety

Keywords

  • Arbutamine
  • Dobutamine
  • Dogs
  • Ischemia
  • Isoproterenol
  • Stress testing

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent. / Nagarajan, Ravi; Abou-Mohamed, Gamal; Myers, Tammy; Caldwell, Robert William.

In: Cardiovascular Drugs and Therapy, Vol. 10, No. 1, 01.01.1996, p. 31-38.

Research output: Contribution to journalArticle

Nagarajan, Ravi ; Abou-Mohamed, Gamal ; Myers, Tammy ; Caldwell, Robert William. / A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent. In: Cardiovascular Drugs and Therapy. 1996 ; Vol. 10, No. 1. pp. 31-38.
@article{bd020c89dfe14bc18010f4fa7ffe445d,
title = "A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent",
abstract = "Arbutamine, developed for use as a cardiac stress agent, was compared with isoproterenol and dobutamine in anesthetized dogs for cardiovascular actions prior to and after beta-adrenergic blockade with propranolol. The efficacy and safety of arbutamine were also evaluated in a canine model of myocardial ischemia obtained by partially occluding the left anterior descending coronary artery. Comparison of hemodynamic variables in normal dogs showed that arbutamine was approximately equipotent to isoproterenol in increasing heart rate and cardiac contractility, and in decreasing total peripheral vascular resistance and mean arterial blood pressure. Arbutamine was 210 times more potent than dobutamine in increasing cardiac contractility by 70{\%}; however, at this dose dobutamine exhibited a negative chronotropic response. Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance. In dogs subjected to partial left anterior descending coronary artery occlusion, arbutamine produced significant ST-segment deflections, beginning at a dose of 0.1 nmol/kg/min. Impairment of segment shortening, reflecting cardiac wall motion abnormality, was evident at a dose of 0.3 nmol/kg/min. Isoproterenol did not cause significant changes in these parameters. These results show that arbutamine is capable of producing graded increments in cardiac contractility and rate before and after beta-adrenergic blockade in normal dogs. In dogs subjected to coronary artery occlusion, it is capable of provoking myocardial ischemia at dose levels devoid of toxicity.",
keywords = "Arbutamine, Dobutamine, Dogs, Ischemia, Isoproterenol, Stress testing",
author = "Ravi Nagarajan and Gamal Abou-Mohamed and Tammy Myers and Caldwell, {Robert William}",
year = "1996",
month = "1",
day = "1",
doi = "10.1007/BF00051128",
language = "English (US)",
volume = "10",
pages = "31--38",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - A novel catecholamine, arbutamine, for a pharmacological cardiac stress agent

AU - Nagarajan, Ravi

AU - Abou-Mohamed, Gamal

AU - Myers, Tammy

AU - Caldwell, Robert William

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Arbutamine, developed for use as a cardiac stress agent, was compared with isoproterenol and dobutamine in anesthetized dogs for cardiovascular actions prior to and after beta-adrenergic blockade with propranolol. The efficacy and safety of arbutamine were also evaluated in a canine model of myocardial ischemia obtained by partially occluding the left anterior descending coronary artery. Comparison of hemodynamic variables in normal dogs showed that arbutamine was approximately equipotent to isoproterenol in increasing heart rate and cardiac contractility, and in decreasing total peripheral vascular resistance and mean arterial blood pressure. Arbutamine was 210 times more potent than dobutamine in increasing cardiac contractility by 70%; however, at this dose dobutamine exhibited a negative chronotropic response. Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance. In dogs subjected to partial left anterior descending coronary artery occlusion, arbutamine produced significant ST-segment deflections, beginning at a dose of 0.1 nmol/kg/min. Impairment of segment shortening, reflecting cardiac wall motion abnormality, was evident at a dose of 0.3 nmol/kg/min. Isoproterenol did not cause significant changes in these parameters. These results show that arbutamine is capable of producing graded increments in cardiac contractility and rate before and after beta-adrenergic blockade in normal dogs. In dogs subjected to coronary artery occlusion, it is capable of provoking myocardial ischemia at dose levels devoid of toxicity.

AB - Arbutamine, developed for use as a cardiac stress agent, was compared with isoproterenol and dobutamine in anesthetized dogs for cardiovascular actions prior to and after beta-adrenergic blockade with propranolol. The efficacy and safety of arbutamine were also evaluated in a canine model of myocardial ischemia obtained by partially occluding the left anterior descending coronary artery. Comparison of hemodynamic variables in normal dogs showed that arbutamine was approximately equipotent to isoproterenol in increasing heart rate and cardiac contractility, and in decreasing total peripheral vascular resistance and mean arterial blood pressure. Arbutamine was 210 times more potent than dobutamine in increasing cardiac contractility by 70%; however, at this dose dobutamine exhibited a negative chronotropic response. Beta-adrenergic blockade with propranolol shifted the agonist's dose-response curves for heart rate and contractility to the right; however, low doses of dobutamine exhibited a negative chronotropic effect and increased the total peripheral vascular resistance. In dogs subjected to partial left anterior descending coronary artery occlusion, arbutamine produced significant ST-segment deflections, beginning at a dose of 0.1 nmol/kg/min. Impairment of segment shortening, reflecting cardiac wall motion abnormality, was evident at a dose of 0.3 nmol/kg/min. Isoproterenol did not cause significant changes in these parameters. These results show that arbutamine is capable of producing graded increments in cardiac contractility and rate before and after beta-adrenergic blockade in normal dogs. In dogs subjected to coronary artery occlusion, it is capable of provoking myocardial ischemia at dose levels devoid of toxicity.

KW - Arbutamine

KW - Dobutamine

KW - Dogs

KW - Ischemia

KW - Isoproterenol

KW - Stress testing

UR - http://www.scopus.com/inward/record.url?scp=0029997606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029997606&partnerID=8YFLogxK

U2 - 10.1007/BF00051128

DO - 10.1007/BF00051128

M3 - Article

VL - 10

SP - 31

EP - 38

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 1

ER -